ヤマグチ　ジユンイチ   YAMAGUCHI Jiyun'ichi   山口　淳一    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
言語種別	日本語
発表タイトル	Impact of Warfarin Usage of Hemodialysis Patients Undergoing Percutaneous Coronary Intervention
会議名	第79回日本循環器学会学術集会
主催者	日本循環器学会
学会区分	全国規模の学会
発表形式	ポスター掲示
講演区分	一般
発表者・共同発表者	◎神島一帆, 山口淳一, 大槻尚男, 春木伸太郎, 岡山大, 中尾優, 重城健太郎, 嵐弘之, 南雄一郎, 萩原誠久
発表年月日	2015/04/26
開催地 （都市, 国名）	大阪市
学会抄録	PROGRAM JCS 2015 672
概要	Background; Warfarin use for dialysis patients is contraindication because of higher bleeding and ischemic stroke risk. Dialysis patients are high risk subset of revascularization and stent thrombosis after percutaneous coronary intervention (PCI). It is unclear benefit or disadvantage of warfarin for dialysis patients undergoing PCI.Methods; We analyzed consecutive 247 dialysis patients undergoing PCI. 38 patients had atrial fibrillation (AF) and 49 patients received warfarin therapy. Basic characteristics were similar except AF. Median follow up periods was 577 days.Result; Figure showed Kaplan-meier curve of major adverse cardiac events composite of cardiac death, non fatal Myocardial infarction, target lesion revascularization and stent thrombosis. Warfarin group was significant higher of clinical events. Conclusion; Warfarin is not beneficial in reducing MACE in dialysis patients.